In mammals, the classical B7 molecules expressed on antigen-presenting cells, B7-1 (CD80) and B7-2 (CD86), bind the structurally related glycoproteins CD28 and CTLA-4 (CD152), generating costimulatory signals that regulate the activation state of T cells. A recently identified human CD28-like protein, ICOS, also induces costimulatory signals in T cells when crosslinked with antibodies, but it is unclear whether ICOS is part of a B7-mediated regulatory pathway of previously unsuspected complexity, or whether it functions independently and in parallel. Here, we report that, rather than binding B7-1 or B7-2, ICOS binds a new B7-related molecule of previously unknown function that we call LICOS (for ligand of ICOS). At 37°C, LICOS binds only to ICOS but, at lower, non-physiological temperatures, it also binds weakly to CD28 and CTLA-4. Sequence comparisons suggest that LICOS is the homologue of a molecule expressed by avian macrophages and of a murine protein whose expression is induced in non-lymphoid organs by tumour necrosis factor α α (TNFα α). Our results define the components of a distinct and novel costimulatory pathway and raise the possibility that LICOS, rather than B7-1 or B7-2, is the contemporary homologue of a primordial vertebrate costimulatory ligand. 
Results and discussion
ICOS is a disulphide-linked homodimeric T-cell surface glycoprotein of relative molecular mass 55-60 kDa, whose extracellular region, like that of CD28, consists of a single immunoglobulin (Ig) superfamily V-set domain [1] . Unlike CD28, which is constitutively expressed, ICOS can only be detected on the surface of activated CD4 + and CD8 + T cells [1] . ICOS also differs from CD28 in that, when crosslinked with antibodies, it induces the production of the anti-inflammatory cytokine interleukin 10 (IL-10), rather than upregulating the synthesis of IL-2 [1] . The highly conserved amino-acid motif MYPPPY (in the singleletter amino-acid code), required for B7 binding by CD28 and CTLA-4 [2, 3] , is not present in the ICOS sequence, suggesting that it might bind a different ligand [1] . To characterise the binding properties of ICOS, we expressed a chimaeric form of the protein, consisting of the extracellular region of ICOS (residues 1-123) and the Fc portion of human IgG1 (ICOS-Fc). A cDNA fragment encoding this region of ICOS was generated by reverse transcriptase (RT)-PCR, using whole RNA isolated from activated human peripheral blood lymphocytes (PBL), and subcloned into the pIgBOS expression vector [4] . ICOS-Fc, secreted by 293T cells transiently transfected with the construct, was purified by affinity chromatography and gel filtration. Following SDS-PAGE, purified ICOS-Fc behaved as a disulphide-linked homodimer (data not shown).
In surface plasmon resonance (SPR)-based assays performed on a BIAcore apparatus [5] , immobilised ICOS-Fc bound strongly to injected anti-ICOS antibody, F44 [1] , suggesting that the chimaeric protein was correctly folded (data not shown). When soluble monomeric forms of B7-1 and B7-2 (sB7-1 and sB7-2, respectively) were injected over a sensor surface to which ICOS-Fc had been immobilised, however, no interaction was observed at protein concentrations that gave very good binding to CD28-Fc and CTLA-4-Fc immobilised on adjacent sensor surfaces ( Figure 1 ). Moreover, in the reverse orientation, bivalent ICOS-Fc did not bind immobilised sB7-1 or sB7-2 even when injected at concentrations as high as 15 µM (data not shown). These results indicate that B7-1 and B7-2 are unlikely to be physiologically important ICOS ligands.
Given the similarities between ICOS and CD28, we used a 'candidate ligand' approach to identify new potential ICOS-binding protein(s), making the assumption that the ligand(s) would be similar to B7. B7-related gene and expressed sequence tag (EST) sequences were retrieved from databases using the program BLAST [6] and from the literature. Among these, we found an EST (GenBank accession number R23544) initially described by Henry et al. [7] as an uncharacterised B7-related gene they called 'transcription unit D'. Alignments of this and other B7-related sequences (see Figure 2 for limited comparisons) indicated that the new gene encoded a hypothetical protein markedly similar to a chicken B7-like macrophage antigen (chCD80L [8] ). O'Regan et al. [8] identified chCD80L using murine CTLA-4-Fc in an expressioncloning screen for putative chicken B7 homologues. The cross-reaction between CTLA-4 and chCD80L implied that the new human protein might also bind one or more members of the CD28/CTLA-4/ICOS family.
A much larger cDNA sequence (EMBL accession number AB014553), originally isolated from human brain, encompassing the EST and encoding a hypothetical protein called KIAA0653, was subsequently found. Semi-quantitative PCR analysis revealed that this gene is expressed at high levels in human PBL, at somewhat lower levels in the brain and very weakly in most other tissues (A.I. and S.J.D., unpublished observations). After identifying a murine homologue of this gene, sequence comparisons suggested that the cytoplasmic-domain-encoding region of the published human AB014553 transcript contained unspliced intronic sequence; the sequence of cDNA re-isolated from the human B cell line TZ was consistent with this possibility (data not shown). Additional sequence analyses revealed alternative splicing at the extreme end of the cytoplasmic-domain-encoding regions of the murine and human B-cell transcripts (A.I., L.M.S. and S.J.D., unpublished observations). We have renamed the longest translated product of the B-cell transcripts, LICOS. The protein sequences of human and murine LICOS are aligned with those of chCD80L, B7-1 and B7-2 in Figure 2 . The murine sequence is identical to that of B7h, the B7-related protein recently identified by Swallow et al. [9] .
The cDNA encoding the predicted extracellular region of LICOS was cloned from the TZ line and used to generate a chimaeric, biotinylatable form of the protein (sLICOS), fused to domains 3 and 4 of rat CD4. The chimaera was expressed transiently in 293T cells using the expression Residues that are identical in 5/5 or 4/5 sequences are shaded red and those identical in 3/5 sequences are shaded blue. The hLICOS and B7-1 sequences share 34% and 24% identity with the chCD80L sequence, indicating that hLICOS, rather than B7-1, is more likely to be the human homologue of chCD80L. Conserved cysteines are shaded yellow. The numbers above the alignment refer to the hLICOS sequence. The blue and green lines over the sequences mark the predicted signal peptide and transmembrane domain sequences of hLICOS, respectively.
Figure 1
B7-1 and B7-2 bind CD28 and CTLA-4 but not ICOS. Soluble forms of B7-1 and B7-2 -sB7-1 (4 µM) and sB7-2 (10 µM) -were injected over sensor surfaces to which CD22-Fc (red trace), CD28-Fc (magenta trace), CTLA-4-Fc (green trace) or ICOS-Fc (blue trace) were immobilised indirectly via anti-human IgG1 monoclonal antibody R10Z8E9 as described [11] . The proteins were immobilised at the following levels: CD22-Fc, 2,500 response units (RU); CD28-Fc, 2,200 RU; CTLA-4-Fc, 800 RU; and ICOS-Fc, 1,700 RU. The experiment was carried out at 25°C. The responses observed when CD22-Fc was immobilised had previously been shown to be the same as those in flow cells to which no protein had been immobilised (data not shown). The expression of monomeric forms of sB7-1 and sB7-2 is described elsewhere ( vector pEF-BOS [10] , and purified from the tissue culture supernatant by OX68 anti-CD4 affinity chromatography and gel filtration. A tetrameric form of sLICOS (sLICOStet), generated by re-purifying the biotinylated chimaeric protein by gel filtration after mixing it with avidin, bound strongly to activated T cells expressing ICOS (data not shown), indicating that the sLICOS preparation was correctly folded. In SPR-based binding assays, monomeric sLICOS bound strongly to ICOS-Fc immobilised on a sensor surface but not to CD28-Fc, CTLA-4-Fc or the negative control protein CD22-Fc immobilised on adjacent surfaces (Figure 3a) . The affinity of the interaction of sLICOS with ICOS-Fc was determined by saturation binding analysis (Figure 3b) . A plot of specific binding response versus sLICOS concentration indicated that binding was saturable (data not shown), and Scatchard analysis of the binding data (Figure 3b , inset) yielded a solution LICOS-ICOS affinity (K d = 4 µM) similar to that of the CD28-B7-1 interaction [11] .
The ligand-binding properties of LICOS were further characterised using multivalent sLICOStet to enhance the sensitivity of the analysis. At 37°C, sLICOStet bound strongly to ICOS-Fc but not to CD28-Fc or CTLA-4-Fc, as expected (Figure 4a) . At a lower, non-physiological temperature (25°C), however, sLICOStet bound CD28-Fc and CTLA-4-Fc (Figure 4b, left sensogram) . The cross-reactive binding was highly specific as it was completely blocked with antibodies that prevent B7-1 and B7-2 binding to CD28 and CTLA-4 ( Figure 4b , right sensogram, for example).
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Figure 3
LICOS binds strongly to ICOS but not CD28 or CTLA-4. (a) Injections, at 25°C, of sLICOS (4 µM) over sensor surfaces to which CD22-Fc (red trace), CD28-Fc (magenta trace), CTLA-4-Fc (green trace) or ICOS-Fc (blue trace) were immobilised. Proteins were immobilised at the levels described in the legend to Figure 1. (b) Injections, at 37°C , of sLICOS at a range of concentrations (26 µM and five twofold dilutions thereof), through a flow cell to which ICOS-Fc was immobilised at a level of 1,500 RU. The cross-reactivity revealed by the binding assays at low temperatures, although clearly non-physiological, suggests that in the course of their evolutionary history ICOS, CD28 and CTLA-4 have all been ligands for LICOS. Sequence alignments (Figure 2 ) indicate that chCD80L is more likely to be the chicken homologue of LICOS than of B7-1, and BLAST searches have identified a chicken ICOS gene and two other B7-like molecules, but no authentic B7-1 or B7-2 homologues (our unpublished data). Together, these observations suggest that LICOS is the contemporary homologue of a protein that may have predated the classical costimulatory molecules and functioned as a primordial ligand for early CD28-like molecules.
Swallow et al. [9] have recently shown that B7h enhances T-cell proliferation through an undefined ligand distinct from CD28 and CTLA-4. Taken with our observation that human ICOS binds the putative human homologue of B7h, this strongly suggests that ICOS-LICOS interactions may generate costimulatory signals in T cells. Significantly, although B7h is constitutively expressed on murine B cells, its expression is upregulated in non-lymphoid tissues treated with lipopolysaccharide (LPS), a potent activator of the inflammatory cytokine TNFα [5] . This contrasts with B7-1 and B7-2, which are expressed almost exclusively on 'professional' antigen-presenting cells. Given that ICOS is expressed only on activated T cells and that its ligand is readily induced in the periphery by inflammatory cytokines, it would appear that a key function of the ICOS-LICOS interaction is to augment local T-cell proliferation at a site of tissue damage or infection. This contrasts with the classical costimulatory enhancement of naïve T-cell activation mediated by CD28-B7 interactions in lymph nodes [12] [13] [14] . Identification of the ICOS ligand should allow rapid progress in understanding the immunological role of this new costimulatory pathway in immunity and disease.
